Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ES102 monotherapy in advanced solid tumors
NCT04730843Phase 1Completed
- Sponsor
- Elpiscience
- Start
- Apr 2021
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of inbrx-106 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), Esophageal Squamous Cell Carcinoma (ESCC) and 3 more (2 arms), sponsored by Elpiscience. Primary endpoints: Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) of ES102 and Number of participants with adverse events and serious adverse events. Started Apr 2021; status: completed.
02
Drugs
inbrx-106
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)Esophageal Squamous Cell Carcinoma (ESCC)nasopharyngeal carcinoma (NPC)Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04730843.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04730843.